Yingjie Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yingjie Ren has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jian Zhou
Department of Laboratory Medicines The First Affiliated Hospital of Xi'an Medical University Xi'an People's Republic of China
1 shared publication - Lijuan Yu
Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Medical University, Guangzhou, China;Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication - Lin Lei
Department of Clinical Laboratory Medicine, Xi'an Hospital of Traditional Chinese Medicine, Xi’an, China
1 shared publication - Xin Wang
The First Affiliated Hospital of Xi'an Jiaotong University
1 shared publication - Zhuo Li
Department of Clinical Laboratory , First Affiliated Hospital of Xi’an Medical University , Xi’an , China
1 shared publication
Latest Publications
- Open Access
- 11 June 2025
- Published by Springer Nature in Research Square
miRNA-375 Combined EB-DNA as Differential Diagnostic Biomarker for EBV-IM and EBV-HLH in Children
In children, Epstein-Barr Virus (EBV) often causes infectious mononucleosis (EBV-IM) but can escalate to a severe condition called EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Differentiating these conditions is vital for proper treatment and prognosis. This study aimed to find plasma biomarkers to distinguish between EBV-IM and EBV-HLH. A retrospective analysis was performed on 17 children with EBV-IM and 23 with EBV-HLH. Selected microRNAs (miRNAs) were measured in plasma using qPCR, and EBV DNA was isolated and quantified. Biomarker effectiveness was assessed using constructing receiver operating characteristic (ROC) curves and the area under the curve (AUC) calculations. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed a significant enrichment of miR-375, miR-148a-3p, and miR-92a-1-5p within the Viral Carcinogenesis pathway. Quantitative PCR validation demonstrated a marked upregulation of miR-375 and miR-148a-3p in patients with EBV-HLH compared to those with EBV-IM, whereas the expression of miR-92a-1-5p did not show a statistically significant difference between the groups. Notably, receiver operating characteristic (ROC) analysis indicated that the combined evaluation of miR-375 and EBV-DNA load achieved superior diagnostic discrimination between EBV-HLH and EBV-IM, with an AUC of 0.951, highlighting its potential high clinical utility. The integrated biomarker panel, consisting of miR-375 and EBV-DNA load, demonstrated high diagnostic accuracy in distinguishing between EBV-HLH and EBV-IM. These findings offer a clinically applicable tool for precise differential diagnosis and therapeutic stratification.
- 11 June 2025
- Published by Springer Nature in Research Square
Open AccessmiRNA-375 Combined EB-DNA as Differential Diagnostic Biomarker for EBV-IM and EBV-HLH in Children
In children, Epstein-Barr Virus (EBV) often causes infectious mononucleosis (EBV-IM) but can escalate to a severe condition called EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Differentiating these conditions is vital for proper treatment and prognosis. This study aimed to find plasma biomarkers to distinguish between EBV-IM and EBV-HLH. A retrospective analysis was performed on 17 children with EBV-IM and 23 with EBV-HLH. Selected microRNAs (miRNAs) were measured in plasma using qPCR, and EBV DNA was isolated and quantified. Biomarker effectiveness was assessed using constructing receiver operating characteristic (ROC) curves and the area under the curve (AUC) calculations. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed a significant enrichment of miR-375, miR-148a-3p, and miR-92a-1-5p within the Viral Carcinogenesis pathway. Quantitative PCR validation demonstrated a marked upregulation of miR-375 and miR-148a-3p in patients with EBV-HLH compared to those with EBV-IM, whereas the expression of miR-92a-1-5p did not show a statistically significant difference between the groups. Notably, receiver operating characteristic (ROC) analysis indicated that the combined evaluation of miR-375 and EBV-DNA load achieved superior diagnostic discrimination between EBV-HLH and EBV-IM, with an AUC of 0.951, highlighting its potential high clinical utility. The integrated biomarker panel, consisting of miR-375 and EBV-DNA load, demonstrated high diagnostic accuracy in distinguishing between EBV-HLH and EBV-IM. These findings offer a clinically applicable tool for precise differential diagnosis and therapeutic stratification.